M24-287: A Study to evaluate the risk of tumor lysis syndrome in adults receiving oral venetoclax combination with obinutuzumab or acalabrutinib for chronic lymphocytic leukaemia (CLL)
The aim of this trial is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of chronic lymphocytic leukaemia (CLL).
You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT06428019
Trial aim and background
The aim of this trial is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL.
Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib at different dosing schemes as part of treatment.
There might be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Who can enter
Adults with previously untreated CLL might be eligible for this trial.
Locations
Recruitment is taking place at Nottingham City Hospital.
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT06428019
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.